Cochlear (OTCMKTS:CHEOF – Get Free Report) and Ainos (OTCMKTS:AIMD – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.
Insider and Institutional Ownership
22.5% of Cochlear shares are held by institutional investors. Comparatively, 0.3% of Ainos shares are held by institutional investors. 4.6% of Ainos shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Cochlear and Ainos’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Cochlear | N/A | N/A | N/A |
Ainos | -515.80% | -44.32% | -40.35% |
Earnings and Valuation
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Cochlear | N/A | N/A | N/A | $1.64 | 143.03 |
Ainos | $93,677.00 | 47.01 | -$14.01 million | ($2.55) | -0.27 |
Cochlear has higher earnings, but lower revenue than Ainos. Ainos is trading at a lower price-to-earnings ratio than Cochlear, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Cochlear and Ainos, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Cochlear | 0 | 0 | 0 | 0 | N/A |
Ainos | 0 | 0 | 0 | 0 | N/A |
Summary
Cochlear beats Ainos on 6 of the 8 factors compared between the two stocks.
About Cochlear
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.
About Ainos
Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.
Receive News & Ratings for Cochlear Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cochlear and related companies with MarketBeat.com's FREE daily email newsletter.